摘要
目的:比较ST段抬高型心肌梗死(STEMI)患者随机接受依诺肝素或普通肝素(UFH)作为溶栓的辅助治疗策略的结果。方法和结果:在ExTRACT-TIMI25临床试验中,20479例接受纤维蛋白特异性溶栓剂(n=16283)或链激酶(SK;n=4139)溶栓治疗STEMI的患者被随机分为依诺肝素(整个住院期间应用)治疗组或UFH(至少应用48h)治疗组。主要终点为30d内发生死亡或非致死性复发心肌梗死。在接受纤维蛋白特异性溶栓剂治疗的患者中,
Aims: We compared outcomes of ST-elevation myocardial infarction(STEMI) patients randomized to a strategy of either enoxaparin or unfractionated heparin(UFH) to support fibrinolysis. Methods and results: In the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction Study 25(ExTRACT-TIMI 25) trial, 20 479 patients undergoing fibrinolysis for STEMI with a fibrin-specific agent(N=16 283) or streptokinase(SK)(N=4139) were randomized to enoxaparin ...
